Profile
Judith A.
Fox is the founder of Foxbiopharma LLC, which was founded in 2013.
She worked as a Senior Director-Translational Sciences Department at Chiron Corp.
from 2005 to 2006, and as a Senior Director & Senior Staff Scientist at Genencor International, Inc. from 2002 to 2005.
From 2006 to 2013, she worked at Sunesis Pharmaceuticals, Inc. as a Vice President-Product & Preclinical Development.
She later returned to Sunesis Pharmaceuticals, Inc. in 2017 as the Chief Scientific Officer & Executive VP, a position she held until 2021.
She also worked as a Senior Vice President-Research & Development at Amphivena Therapeutics, Inc. Dr. Fox holds a doctorate degree from Massachusetts Institute of Technology and an undergraduate degree from Bryn Mawr College.
Former positions of Judith A. Fox
Companies | Position | End |
---|---|---|
VIRACTA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2021-02-23 |
VIRACTA THERAPEUTICS, INC. | Corporate Officer/Principal | 2012-12-31 |
Chiron Corp.
Chiron Corp. Medical SpecialtiesHealth Technology Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA. | Corporate Officer/Principal | 2005-12-31 |
Genencor International, Inc.
Genencor International, Inc. BiotechnologyHealth Technology Genencor International, Inc. develops and manufactures enzyme product solutions for industrial, agricultural and health care markets. It finds genes and alters their proteins for use in cleaning, textile, health care, food and animal feed products using gene discovery, molecular evolution, functional genomics and immunology techniques. The company also develops solutions for the biofuels, biodefense and biosafety industries. Genencor International was founded in 1982 and is located in Rochester, NY. | Director/Board Member | 2004-12-31 |
Foxbiopharma LLC | Founder | - |
Training of Judith A. Fox
Massachusetts Institute of Technology | Doctorate Degree |
Bryn Mawr College | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 5 |
---|---|
Chiron Corp.
Chiron Corp. Medical SpecialtiesHealth Technology Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA. | Health Technology |
Genencor International, Inc.
Genencor International, Inc. BiotechnologyHealth Technology Genencor International, Inc. develops and manufactures enzyme product solutions for industrial, agricultural and health care markets. It finds genes and alters their proteins for use in cleaning, textile, health care, food and animal feed products using gene discovery, molecular evolution, functional genomics and immunology techniques. The company also develops solutions for the biofuels, biodefense and biosafety industries. Genencor International was founded in 1982 and is located in Rochester, NY. | Health Technology |
Sunesis Pharmaceuticals, Inc.
Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Amphivena Therapeutics, Inc.
Amphivena Therapeutics, Inc. Drugstore ChainsRetail Trade Amphivena Therapeutics, Inc. provides drug discovery services. It develops tetravalent, T-cell redirecting bispecific antibodies for the treatment of hematologic malignancies. The firm’s’ lead drug candidate is AMV-564, a CD33/CD3-targeting treatment for acute myeloid leukemia (AML), which Amphivena is currently preparing to advance into clinical development. The company was founded by Jeanmarie Guenot in December 2012 and is headquartered in San Francisco, CA. | Retail Trade |
Foxbiopharma LLC |
- Stock Market
- Insiders
- Judith A. Fox